Hype and biotech go hand in hand, but genomics takes exaggeration up a few extra notches. When genomics companies fail, they tend to crash especially hard. Yet every now and then, a company that’s monumentally hyped falls flat and then figures out a way to become a solid, if not spectacular, player. That’s the storyline that’s slowly taken shape at Pacific Biosciences. Menlo Park, CA-based PacBio (NASDAQ: PACB), readers may recall, had a few minutes of fame on Wall Street.
Help employers find you! Check out all the jobs and post your resume.
